We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

IRESSA™ (Gefitinib) in Breast Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00632723
First Posted: March 11, 2008
Last Update Posted: April 22, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxifen and 27 patients with ER negative tumours. However for each of these two types of patients recruitment will stop after 14 patients have been entered in order to confirm that IRESSA™ (gefitinib)has anti-tumour efficacy. If no patient out of 14 in a group has shown clinical benefit (ie an objective response (CR or PR) or stable disease (SD) for at least 24 weeks) then a clinical benefit rate of >20% can be ruled out with >95% certainty. If one or more of the objective response or stable disease (> 24 weeks) has been seen in the first 14 patients recruited in a group then recruitment to that group will recommence to a total of 27 patients. If 14 patients are entered into an arm but not all 14 patients are available for final analysis and the toxicity/safety and tolerability profile of the therapy is acceptable and documented and a clinical benefit is seen in the patients, enrolment of additional patients beyond the initial 14 may be made based on overall clinical assessment.

Condition Intervention Phase
Breast Cancer Drug: gefitinib (IRESSA™, ZD1839) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Objective tumour response (complete + partial response) based on Union International Contre le Cancer (UICC) Criteria [ Time Frame: Assessed after 24 weeks ]
  • Clinical benefit (CR + PR + SD > 24 wks) [ Time Frame: After 24 weeks of treatment ]
  • Frequency and severity of adverse events (AEs) [ Time Frame: Assessed at each visit ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: Time to death ]
  • Duration of response [ Time Frame: Time to progression ]

Enrollment: 54
Study Start Date: April 2001
Study Completion Date: October 2005
Intervention Details:
    Drug: gefitinib (IRESSA™, ZD1839)
    250 mg tablet; daily dose 500 mg daily
    Other Names:
    • IRESSA™
    • ZD1839
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histological or cytological confirmation of breast cancer that is either

    • a primary tumour in a patient unfit for or who has declined surgery
    • advanced (locally or metastatic) disease
  • acquired resistance to tamoxifen or ER negative tumour
  • at least one measurable or assessable lesion
  • WHO performance status 0 - 2
  • life expectancy of 12 weeks or more

Exclusion Criteria:

  • more than one previous chemotherapy regimens for advanced disease
  • prior anthracycline chemotherapy (> 250 mg/m2 adriamycin)
  • radiotherapy completed within 14 days prior to Day 1 of treatment
  • incomplete healing from prior oncologic or other major surgery
  • signs of neurological symptoms consistent with spinal cord compression
  • any evidence of clinically active interstitial lung disease (patients with chronic stable
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00632723


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: R Robertson, MD City Hospital, Nottingham , UK
  More Information

Responsible Party: Pauline Pert, Clinical Leader, AZ UK MC, AstraZeneca
ClinicalTrials.gov Identifier: NCT00632723     History of Changes
Other Study ID Numbers: 1839IL/0057
First Submitted: January 17, 2008
First Posted: March 11, 2008
Last Update Posted: April 22, 2009
Last Verified: April 2009

Keywords provided by AstraZeneca:
oestrogen receptor
ER negative tumours
epidermal growth factor receptor (EGFR)

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Estrogens
Gefitinib
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action